An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

NCT01386580 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Brain Metastases
Lung Cancer
Breast Cancer
Melanoma
Malignant Glioma

Interventions

DRUG: 2B3-101
DRUG: Trastuzumab
DRUG: 2B3-101 60 mg/m2 every 4 weeks
DRUG: 2B3-101 50 mg/m2 every 3 weeks

Sponsor

BBB-Therapeutics B.V.